Description
Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is an eye drop used to decrease intraocular pressure in patients diagnosed with open-angle glaucoma or increased fluid pressure in the eye.
Fact Table
|
Formula
|
Brinzolamide: C12H21N3O5S3 Brimonidine: C11H10BrN5
|
License
|
EU EMA, US DailyMed
|
Bioavailability
|
Brinzolamide: Absorbed systemically, but below detectable levels (less than 10 ng/mL) Brimonidine: Not Available
|
Legal status
|
Prescription only
|
Chemical Name
|
Brinzolamide/Brimonidine Tartrate
|
Elimination half-life
|
111 days (Brinzolamide), Brimonidine: 3 hours (ocular), 12 hours (topical)
|
Dosage (Strength)
|
1% / 0.2% 5ml
|
Pregnancy
|
Consult Doctor
|
Brands
|
Simbrinza Opthalmic
|
Protein binding
|
60%
|
PubChem CID
|
68844
|
MedlinePlus
|
a601233
|
ChEBI
|
3176
|
ATC code
|
S01EC04
|
DrugBank
|
DB01194
|
KEGG
|
D00652
|
Routes of administration
|
Ophthalmic
|
Directions
Follow your doctor's instructions and carefully read the information that comes with your Simbrinza prescription to ensure that you know how and when to administer the eye drops. If you have further questions, ask your doctor or pharmacist.
If you wear contact lenses, remove them before using Simbrinza. You may put them back in 15 minutes after Simbrinza use.
Do not let the tip of the bottle touch any surface.
Before instilling the eye drops, shake the bottle well. Place one drop in the affected eye(s) three times a day. If you use other eye drops, wait at least 5 minutes before using them.
Ingredients
Simbrinza contains two active ingredients-brinzolamide and brimonidine tartrate. Boric acid, carbomer 974P, mannitol, propylene glycol, purified water, sodium chloride, and tyloxapol are the inactive ingredients. Benzalkonium chloride is added as a preservative and hydrochloric acid and/or sodium hydroxide may be added to balance the pH.
Contraindications
Patients who are allergic to brinzolamide, brimonidine tartrate, or any of the other ingredients in the medication should not use Simbrinza.
Newborns and infants younger than 2 years old should not use Simbrinza.
Cautions
- Before starting treatment with Simbrinza, inform your doctor of the following:
- All the medications you take
- Any allergies you may have
- Your medical history and active health problems
- If you are pregnant or plan to become pregnant
- If you are breastfeeding or plan to breastfeed
- Brinzolamide, one of the active ingredients in Simbrinza, is a sulfonamide. Allergic reactions that may be severe can occur in patients who are allergic to sulfonamides. Seek medical care right away if you have trouble breathing, swelling, a rash, or other skin reaction.
- Swelling of the cornea can occur in patients with low endothelial cell counts while using Simbrinza.
- Brinzolamide, one of the active ingredients in Simbrinza, and its metabolite are excreted by the kidney; therefore, use of Simbrinza should be avoided in patients with severe kidney problems.
- Other therapies along with medications that lower fluid pressure in the eye(s) should be used to treat acute angle-closure glaucoma. The use of Simbrinza has not been studied in patients who have been diagnosed with acute angle-closure glaucoma.
- Caution should be used in patients with severe heart disease.
- Caution should be used in patients with severe liver problems because brimonidine tartrate, one of the active ingredients in Simbrinza, has not been studied in these patients.
- Caution should be used in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, low blood pressure upon standing, or thromboangitis obliterans because brimonidine tartrate, one of the active ingredients in Simbrinza, can cause syndromes related to vascular insufficiency.
Side Effects
Blurred vision, eye irritation, altered taste, dry mouth, and eye allergy are the most common side effects associated with the use of Simbrinza eye drops. These are not all the Simbrinza side effects, so be sure to let your doctor know if you have side effects that are bothersome or won't go away.
Reference:
Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%. Fort Worth, TX: Alcon Laboratories, Inc; 2021.
About Dr. Savannah Muncy (Page Author)
Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 13205